Cart
sales@molnova.com
Fluorogenic Human CMV Protease Substrate
CAS No. 163265-38-1
Fluorogenic Human CMV Protease Substrate( ——— )
Catalog No. M39903 CAS No. 163265-38-1
Dabcyl-RGVVNASSRLA-Edans (Dabcyl-CMV-Edans) is a fluorogenic substrate for human cytomegalovirus (HCMV) protease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameFluorogenic Human CMV Protease Substrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionDabcyl-RGVVNASSRLA-Edans (Dabcyl-CMV-Edans) is a fluorogenic substrate for human cytomegalovirus (HCMV) protease.
-
DescriptionDabcyl-RGVVNASSRLA-Edans (Dabcyl-CMV-Edans) is a fluorogenic substrate for human cytomegalovirus (HCMV) protease.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number163265-38-1
-
Formula Weight1628.85
-
Molecular FormulaC73H109N23O18S
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Holskin BP, et al. A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate. Anal Biochem. 1995 May 1;227(1):148-55. ?
molnova catalog
related products
-
L-Phenylalanine beta...
L-Phenylalanine betaine
-
PALATINOSE
PALATINOSE is a natural occurring disaccharide composed of alpha-1,6-linked glucose and fructose, synergetic inhibitory effect on lung metastasis of LA795 xenograft tumor.
-
Oleanic aldehyde
Oleanolic aldehyde is an antimicrobial compound used to inhibit oral bacteria. Oleanolic aldehyde inhibits Streptococcus mutans and Porphyromonas gingivalis, which are associated with dental caries and periodontal disease, with minimum inhibitory concentrations (MICs) of 488 μg/mL and 250 μg/mL, respectively.
